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Abstract 
Cardiac myxoma is a rare but curable cause of ischemic stroke. Current guidelines do not 
address the use of intravenous thrombolysis for embolic stroke caused by cardiac 
myxoma. The risk of hemorrhage due to occult tumor emboli or microaneurysms is a 
major concern. We describe a 45-year-old man who had an embolic stroke in the left 
middle cerebral artery. The initial National Institutes of Health Stroke Scale (NIHSS) score 
was 16. He received intravenous thrombolysis 2 h and 52 min after stroke onset. No 
intracranial hemorrhage developed. A cardiac mass was found in the left atrium and 
removed surgically 84 h after stroke. Pathological study showed a myxoma with 
extensive hemorrhage and thrombus over the surface. At the 3-month follow-up, the 
NIHSS score was 9 and the modified Rankin scale score was 3. Our experience with this 
patient supports the hypothesis that intravenous thrombolysis may be safely used in the 
treatment of embolic stroke due to cardiac myxoma. 
 
Introduction 
Left atrial myxoma is a rare but curable cause of ischemic stroke. Embolic stroke and 
transient ischemic attack are among the common manifestations [1–3]. In a hospital-
based series, stroke occurred in 20.3% (23/112) of patients with left atrial cardiac myxoma 
[1]. In a review of neurological manifestations of cardiac myxoma, hemorrhagic stroke 
could be found in 16.8% (19/113) and ischemic stroke in 82.3% (93/113) of all cases [3], 
and stroke caused significant disability in most patients. Intravenous thrombolysis is an 
important treatment for ischemic stroke. However, experience in using intravenous 
thrombolysis for the treatment of embolic stroke due to left atrial myxoma is limited.  
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Case Report 
A 45-year-old male without known cardiovascular risk factors had a sudden onset of right limb 
weakness and difficulty in verbal expression. Upon arrival at the emergency department, his blood 
pressure was 118/74 mm Hg, the heart rate was 82 bpm and regular, and the body temperature was 
37.0°C. An electrocardiogram showed sinus rhythm and incomplete right branch bundle block. On  
X-ray, an enlargement of the cardiac silhouette was noted. The National Institutes of Health Stroke 
Scale (NIHSS) score was 16 and the head CT scan was normal. All criteria for intravenous thrombolysis 
were met, thus the patient received 0.9 mg/kg i.v. recombinant tissue plasminogen activator (rtPA, a 
total of 54 mg) per standard protocol 47 min after arrival at the emergency department and 2 h and 52 
min after symptom onset. A follow-up CT scan revealed hypodense lesions in the left basal ganglia and 
corona radiata without evidence of hemorrhage (fig. 1a). There was no change in the NIHSS score 24 h 
after treatment. An urgent transthoracic echocardiogram was carried out because of the enlargement of 
the cardiac silhouette seen on the chest X-ray. A large mass with irregular shape within the left atrium 
was found. This finding was confirmed with a CT scan of the chest and the heart (fig. 1b). Urgent 
cardiac surgery was performed 84 h after presentation. A large, reddish, elastic mass, 8.0 × 4.7 × 3.7 cm 
in size, was removed from the left atrium. The cut surface of the atrial tumor revealed a gelatinous 
texture with a congested and irregular surface. There was also a cystic degeneration in the central 
portion (fig. 2a). Microscopically, the irregular surface of the atrial tumor was hemorrhagic and focally 
coated with blood clots composed of blood cells admixed with fibrinous material. In a high-power field, 
polygonal and spindle-shaped tumor cells were arranged in a single cord or in nests within the myxoid 
stroma with some capillary-sized vessels (fig. 2b). The tumor cells were calretinin positive and CD31 
negative, which differentiate them from endothelial cells of the granulation tissue or endocardial cells 
(fig. 2c). The findings were diagnostic of cardiac myxoma. The patient was discharged to receive 
rehabilitation. At the 3-month follow-up, the NIHSS score was 9 and the modified Rankin scale score 
was 3. 
Discussion 
Cardiac myxoma is the most common primary tumor of the heart and more prevalent 
in women than in men [1]. Age at diagnosis is usually less than 60 years. In a study by 
Alvarez-Sabín et al. [2], patients with neurological events were younger at diagnosis than 
those without neurological manifestations (mean 49 vs. 61 years). The most common 
initial symptoms of left atrial myxoma include cardiac manifestations such as heart 
failure, syncope, or arrhythmias, systemic manifestations such as fever, weight loss, or 
fatigue, and embolic events such as cerebral embolism, peripheral embolism, or coronary 
embolism. Embolic stroke is the most common neurological manifestation [1–3]. 
To our knowledge, the use of intravenous thrombolytic therapy in embolic stroke 
caused by cardiac myxoma has only been reported in 4 cases [4–7]. The first reported case 
presented with cerebellar hemorrhage and parietal subarachnoid hemorrhage 5 h after 
treatment [4]. The tumor was 3 × 4 cm in size, very friable, and gelatinous and 
fragmented easily with minimal manipulation. The hemorrhages were suspected to be 
secondary to tumor emboli or microaneurysms. Sabolek et al. [8] found cerebral 
aneurysms in patients with cardiac myxoma, with a median number of 3.0 aneurysms per 
patient. Thus, the safety of intravenous thrombolysis in these patients was a concern. The 
greater risk of hemorrhage due to occult tumor emboli or microaneurysms should 
therefore be considered. 
Three later reported cases of intravenous thrombolysis for ischemic stroke caused by 
cardiac myxoma were all successful [5–7], and no hemorrhage occurred. The three cases 
were younger and had shorter onset-to-treatment times than the first reported case (table 
1). The tumor in one case was 6.4 × 5.0 × 4.0 cm in size and encapsulated [6]. Although  
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morphology of the other case was not addressed, thrombus rather than tumor embolus 
was presumed to be the cause of the stroke [5]. Emboli due to cardiac myxomas are often 
tumor fragments but may also arise from a thrombus that is formed on the surface of the 
myxoma [9]. Tumor emboli are presumably less responsive to thrombolytic therapy [4–
6]. Pathological results in our case demonstrated extensive hemorrhage and inflammatory 
infiltrate of the tumor as well as a thrombus over the surface. In our patient, emboli could 
be a pure thrombus or thrombotic propagation of tumor material. 
Intra-arterial thrombolysis following diagnostic angiography is thought to minimize 
the risk of hemorrhage in patients with cardiac myxoma by excluding a pseudoaneurysm 
and minimizing fibrinolytic exposure to unaffected vessels [10]. To our knowledge, there 
are two reported cases of intra-arterial thrombolysis for stroke due to cardiac myxoma in 
the literature [10, 11]. A 57-year-old woman with right middle cerebral artery occlusion 
was treated with 1 MU urokinase 3.5 h following the onset of symptoms. Although there 
was no intracranial hemorrhage, the patient died. Significant brain swelling with 
subfalcine herniation and subsequent transtentorial herniation was found [10]. The other 
case was a 62-year-old woman with right middle cerebral artery occlusion. She was 
treated with rtPA within 3 h after stroke. Partial re-canalization was obtained without 
hemorrhage. She returned to work 9 months after receiving treatment [11]. 
In a study by Ekinci and Donnan [3], hemorrhagic stroke (intracerebral hemorrhage 
and subarachnoid hemorrhage) could be found in 16.8% (19/113) of neurological 
manifestations of cardiac myxoma. For our case and other reported cases with 
intravenous rtPA thrombolysis, the rate of intracranial hemorrhage was 20% (1/5). If 
cases with intra-arterial thrombolysis are included, the rate was 16.7% (1/6) for rtPA 
thrombolysis and 14.3% (1/7) for all thrombolysis cases. In the Safe Implementation of 
Thrombolysis in Stroke-Monitoring Study [12], the rate of intracerebral hemorrhages 
detected by CT or MRI was 14.5% (869/6,283) 22–36 h after intravenous rtPA 
thrombolysis and 17.1% (1,085/6,352) in any post-treatment imaging scans. Intravenous 
thrombolytic therapy for acute stroke requires a timely process to shorten the time to 
treatment [13]. Current guidelines do not deal with cardiac myxoma. In addition, the 
diagnosis of cardiac myxomatous embolism is rarely made before treatment. Although 
the number of reported cases is small, intravenous thrombolytic therapy for stroke caused 
by cardiac myxoma might not be as risky as previously thought. 
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Table 1. Clinical manifestation of patients with intravenous thrombolysis for embolic stroke due to 
cardiac myxoma 
Reference Age/ 
sex 
OTT  
min 
NIHSS 
score 
Intracranial  
hemorrhage 
Outcome 
Chong et al. [4]  74/F  180    6 yes  aphasia 
Ibrahim et al. [5]  51/M  084 22  no  complete  recovery 
Nagy et al. [6]  26/M  105  10  no  minimal hand weakness at 2 years 
Ong and Chang [7]  22/F  125  12  no  NIHSS score 5 at 10 months 
This report  45/M  172  16  no  motor aphasia and right hemiparesis at 3 months 
OTT = Onset-to-treatment time. 
 
 
 
Fig. 1. Head CT scan 27 h after thrombolysis shows hypodense lesions in the left basal ganglia and 
corona radiata without evidence of hemorrhage (a). CT scan of the chest and the heart with contrast 
shows a large filling defect in the left atrium (b). 
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Fig. 2. A photomicrograph of the 8.0 × 4.7 × 3.7 cm cardiac tumor removed at the operation (a). 
Microscopically, polygonal and spindle cells were arranged in a single cord or in nests and embedded in 
the myxoid stroma (HE) (b). The tumor cells show immunoreactivity to calretinin 
(immunohistochemical stain, anti-calretinin) (c). 
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